M
27.05
0.49 (1.84%)
| Previous Close | 26.56 |
| Open | 26.92 |
| Volume | 12,833,551 |
| Avg. Volume (3M) | 11,001,090 |
| Market Cap | 10,461,371,392 |
| Price / Sales | 4.20 |
| Price / Book | 1.24 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -110.04% |
| Operating Margin (TTM) | -128.99% |
| Diluted EPS (TTM) | -9.28 |
| Quarterly Revenue Growth (YOY) | -65.60% |
| Total Debt/Equity (MRQ) | 6.85% |
| Current Ratio (MRQ) | 3.67 |
| Operating Cash Flow (TTM) | -3.00 B |
| Levered Free Cash Flow (TTM) | -3.09 B |
| Return on Assets (TTM) | -15.14% |
| Return on Equity (TTM) | -28.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Moderna, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.9
| Analyst Consensus | -0.5 |
| Insider Activity | -4.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.90 |
|
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 7.27% |
| % Held by Institutions | 72.80% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Theleme Partners Llp | 31 Mar 2025 | 7,242,390 |
| Flagship Pioneering Inc. | 31 Mar 2025 | 4,632,149 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (UBS, 158.78%) | Buy |
| Median | 32.00 (18.30%) | |
| Low | 26.00 (JP Morgan, -3.88%) | Sell |
| Average | 38.29 (41.55%) | |
| Total | 1 Buy, 5 Hold, 1 Sell | |
| Avg. Price @ Call | 28.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 22 May 2025 | 26.00 (-3.88%) | Sell | 26.72 |
| 21 Mar 2025 | 33.00 (22.00%) | Sell | 32.66 | |
| Barclays | 02 May 2025 | 40.00 (47.87%) | Hold | 27.61 |
| Evercore ISI Group | 02 May 2025 | 32.00 (18.30%) | Hold | 27.61 |
| RBC Capital | 02 May 2025 | 28.00 (3.51%) | Hold | 27.61 |
| UBS | 02 May 2025 | 70.00 (158.78%) | Buy | 27.61 |
| Morgan Stanley | 09 Apr 2025 | 32.00 (18.30%) | Hold | 26.67 |
| Citigroup | 13 Mar 2025 | 40.00 (47.87%) | Hold | 34.30 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HOGE STEPHEN | - | 26.41 | -990 | -26,283 |
| KLINGER SHANNON THYME | - | 26.41 | -533 | -14,150 |
| MOCK JAMES M | - | 26.41 | -533 | -14,150 |
| Aggregate Net Quantity | -2,056 | |||
| Aggregate Net Value ($) | -54,583 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 26.41 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HOGE STEPHEN | Officer | 28 May 2025 | Disposed (-) | 295 | 26.05 | 7,685 |
| HOGE STEPHEN | Officer | 28 May 2025 | Option execute | 610 | - | - |
| KLINGER SHANNON THYME | Officer | 28 May 2025 | Disposed (-) | 159 | 26.05 | 4,142 |
| KLINGER SHANNON THYME | Officer | 28 May 2025 | Option execute | 328 | - | - |
| MOCK JAMES M | Officer | 28 May 2025 | Disposed (-) | 159 | 26.05 | 4,142 |
| MOCK JAMES M | Officer | 28 May 2025 | Option execute | 328 | - | - |
| HOGE STEPHEN | Officer | 27 May 2025 | Disposed (-) | 695 | 26.76 | 18,598 |
| HOGE STEPHEN | Officer | 27 May 2025 | Option execute | 1,436 | - | - |
| KLINGER SHANNON THYME | Officer | 27 May 2025 | Disposed (-) | 374 | 26.76 | 10,008 |
| KLINGER SHANNON THYME | Officer | 27 May 2025 | Option execute | 773 | - | - |
| MOCK JAMES M | Officer | 27 May 2025 | Disposed (-) | 374 | 26.76 | 10,008 |
| MOCK JAMES M | Officer | 27 May 2025 | Option execute | 773 | - | - |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 31 May 2025 | Announcement | Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE |
| 28 May 2025 | Announcement | Moderna Announces Update on Investigational Pandemic Influenza Program |
| 21 May 2025 | Announcement | Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19 |
| 08 May 2025 | Announcement | Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025 |
| 01 May 2025 | Announcement | Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates |
| 10 Apr 2025 | Announcement | Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 |
| 07 Apr 2025 | Announcement | Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025 |
| 31 Mar 2025 | Announcement | Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults |
| 31 Mar 2025 | CNBC | Vaccine stocks fall after key FDA official resigns in protest of RFK Jr. |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |